Results presented today at the American College of Rheumatology in Boston show that a 12-biomarker test did a better job of predicting radiographic progression in patients with RA. The study ...

The 12-biomarker test is gaining acceptance among rheumatologists and was recently added to a clinical guideline. Starting Sunday, Crescendo Bioscience will present a series of abstracts on its Vectra ...

The use of the Vectra DA test results in the simulated cases was associated with a 12 percent improvement in the quality of disease activity assessment and treatment (p<0.01), and also with a 3 ...

Crescendo Bioscience®, Inc. has announced the online publication of results validating the performance of Vectra™ DA to measure rheumatoid arthritis (RA) disease activity in Arthritis Care & Research, ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — At the American College of Rheumatology Annual Meeting, Elena Hitraya, MD, PhD, chief medical ...

One of the many challenges of a rheumatoid arthritis diagnosis is the condition’s variability from patient to patient and over time. This unpredictability also impacts the effectiveness of drugs used ...

SALT LAKE CITY, Utah, June 10, 2014 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that Vectra® DA data will be featured in eight posters at ...

Vectra DA is the only multi-biomarker blood test for rheumatoid arthritis (RA) disease activity that integrates the concentrations of 12 serum proteins associated with RA disease activity into a ...

Molecular diagnostics company developed and is commercializing first and only multi-biomarker blood test—Vectra TM DA—for rheumatoid arthritis to help physicians make more informed treatment decisions ...

Myriad Genetics, Inc.'s ( MYGN) subsidiary, Crescendo Bioscience has published a new study for its Vectra DA blood test in the Annals of the Rheumatic Diseases online journal. The study is a ...

Myriad Genetics, Inc. 's MYGN subsidiary, Crescendo Bioscience continues to make development with its Vectra DA assay. After last week's announcement of its contract with United Rheumatology on this ...